vs
CytomX Therapeutics, Inc.（CTMX）与NexPoint Real Estate Finance, Inc.（NREF）财务数据对比。点击上方公司名可切换其他公司
CytomX Therapeutics, Inc.的季度营收约是NexPoint Real Estate Finance, Inc.的1.7倍（$18.7M vs $11.1M），NexPoint Real Estate Finance, Inc.净利率更高（216.6% vs -0.8%，领先217.5%），CytomX Therapeutics, Inc.同比增速更快（-25.7% vs -48.8%）
CytomX Therapeutics是一家临床阶段生物技术公司，专注于创新癌症免疫疗法研发，依托专有的Probody技术平台开发仅在肿瘤微环境中激活的靶向疗法，可降低脱靶毒性，管线覆盖多种实体瘤适应症，还与全球头部药企合作推进相关治疗方案开发。
NexPoint Real Estate Finance, Inc.是一家总部位于美国的商业地产金融企业，主要为多户住宅、写字楼、工业及酒店物业提供结构化融资方案，运营并管理抵押贷款及其他地产相关投资组合，为利益相关方提供经风险调整的稳定回报。
CTMX vs NREF — 直观对比
营收规模更大
CTMX
是对方的1.7倍
$11.1M
营收增速更快
CTMX
高出23.1%
-48.8%
净利率更高
NREF
高出217.5%
-0.8%
损益表 — Q2 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $18.7M | $11.1M |
| 净利润 | $-154.0K | $24.0M |
| 毛利率 | — | — |
| 营业利润率 | -6.9% | — |
| 净利率 | -0.8% | 216.6% |
| 营收同比 | -25.7% | -48.8% |
| 净利润同比 | 97.6% | 58.7% |
| 每股收益（稀释后） | — | $0.47 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CTMXNREF
| Q4 25 | — | $11.1M | ||
| Q3 25 | — | $12.5M | ||
| Q2 25 | $18.7M | $12.1M | ||
| Q1 25 | $50.9M | $11.5M | ||
| Q4 24 | $38.1M | $21.7M | ||
| Q3 24 | $33.4M | $12.5M | ||
| Q2 24 | $25.1M | $6.7M | ||
| Q1 24 | $41.5M | $-12.8M |
净利润CTMXNREF
| Q4 25 | — | $24.0M | ||
| Q3 25 | — | $50.9M | ||
| Q2 25 | $-154.0K | $22.3M | ||
| Q1 25 | $23.5M | $26.0M | ||
| Q4 24 | $18.9M | $15.2M | ||
| Q3 24 | $5.7M | $23.3M | ||
| Q2 24 | $-6.5M | $12.1M | ||
| Q1 24 | $13.8M | $-14.6M |
营业利润率CTMXNREF
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -6.9% | — | ||
| Q1 25 | 44.4% | — | ||
| Q4 24 | 46.4% | — | ||
| Q3 24 | 12.3% | — | ||
| Q2 24 | -33.7% | — | ||
| Q1 24 | 28.1% | — |
净利率CTMXNREF
| Q4 25 | — | 216.6% | ||
| Q3 25 | — | 407.0% | ||
| Q2 25 | -0.8% | 184.5% | ||
| Q1 25 | 46.2% | 225.6% | ||
| Q4 24 | 49.6% | 69.9% | ||
| Q3 24 | 17.2% | 186.4% | ||
| Q2 24 | -26.0% | 179.7% | ||
| Q1 24 | 33.3% | 114.3% |
每股收益（稀释后）CTMXNREF
| Q4 25 | — | $0.47 | ||
| Q3 25 | — | $1.14 | ||
| Q2 25 | — | $0.54 | ||
| Q1 25 | — | $0.70 | ||
| Q4 24 | — | $0.71 | ||
| Q3 24 | — | $0.74 | ||
| Q2 24 | — | $0.40 | ||
| Q1 24 | — | $-0.83 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $49.0M | $31.1M |
| 总债务越低越好 | — | $771.2M |
| 股东权益账面价值 | $119.9M | $388.0M |
| 总资产 | $175.1M | $5.3B |
| 负债/权益比越低杠杆越低 | — | 1.99× |
8季度趋势，按日历期对齐
现金及短期投资CTMXNREF
| Q4 25 | — | $31.1M | ||
| Q3 25 | — | $17.9M | ||
| Q2 25 | $49.0M | $9.1M | ||
| Q1 25 | $47.6M | $19.2M | ||
| Q4 24 | $38.1M | $3.9M | ||
| Q3 24 | $40.6M | $34.7M | ||
| Q2 24 | $43.2M | $4.3M | ||
| Q1 24 | $36.2M | $13.5M |
总债务CTMXNREF
| Q4 25 | — | $771.2M | ||
| Q3 25 | — | $720.9M | ||
| Q2 25 | — | $815.6M | ||
| Q1 25 | — | $831.5M | ||
| Q4 24 | — | $799.3M | ||
| Q3 24 | — | $815.5M | ||
| Q2 24 | — | $861.0M | ||
| Q1 24 | — | $843.3M |
股东权益CTMXNREF
| Q4 25 | — | $388.0M | ||
| Q3 25 | — | $375.4M | ||
| Q2 25 | $119.9M | $348.2M | ||
| Q1 25 | $25.0M | $343.7M | ||
| Q4 24 | $-456.0K | $336.5M | ||
| Q3 24 | $-23.5M | $335.8M | ||
| Q2 24 | $-31.2M | $327.5M | ||
| Q1 24 | $-31.7M | $327.1M |
总资产CTMXNREF
| Q4 25 | — | $5.3B | ||
| Q3 25 | — | $5.3B | ||
| Q2 25 | $175.1M | $5.4B | ||
| Q1 25 | $98.5M | $5.4B | ||
| Q4 24 | $120.5M | $5.4B | ||
| Q3 24 | $139.0M | $5.7B | ||
| Q2 24 | $159.2M | $6.6B | ||
| Q1 24 | $184.7M | $7.1B |
负债/权益比CTMXNREF
| Q4 25 | — | 1.99× | ||
| Q3 25 | — | 1.92× | ||
| Q2 25 | — | 2.34× | ||
| Q1 25 | — | 2.42× | ||
| Q4 24 | — | 2.38× | ||
| Q3 24 | — | 2.43× | ||
| Q2 24 | — | 2.63× | ||
| Q1 24 | — | 2.58× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-15.8M | $-4.5M |
| 自由现金流经营现金流 - 资本支出 | $-15.8M | — |
| 自由现金流率自由现金流/营收 | -84.6% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | -0.19× |
| 过去12个月自由现金流最近4个季度 | $-77.7M | — |
8季度趋势，按日历期对齐
经营现金流CTMXNREF
| Q4 25 | — | $-4.5M | ||
| Q3 25 | — | $8.1M | ||
| Q2 25 | $-15.8M | $3.3M | ||
| Q1 25 | $-21.0M | $16.0M | ||
| Q4 24 | $-19.9M | $4.4M | ||
| Q3 24 | $-20.7M | $14.7M | ||
| Q2 24 | $-19.5M | $-7.5M | ||
| Q1 24 | $-26.0M | $17.7M |
自由现金流CTMXNREF
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-15.8M | — | ||
| Q1 25 | $-21.2M | — | ||
| Q4 24 | $-20.0M | — | ||
| Q3 24 | $-20.7M | — | ||
| Q2 24 | $-19.6M | — | ||
| Q1 24 | $-26.2M | — |
自由现金流率CTMXNREF
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -84.6% | — | ||
| Q1 25 | -41.6% | — | ||
| Q4 24 | -52.5% | — | ||
| Q3 24 | -62.1% | — | ||
| Q2 24 | -78.2% | — | ||
| Q1 24 | -63.1% | — |
资本支出强度CTMXNREF
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.4% | — | ||
| Q1 24 | 0.3% | — |
现金转化率CTMXNREF
| Q4 25 | — | -0.19× | ||
| Q3 25 | — | 0.16× | ||
| Q2 25 | — | 0.15× | ||
| Q1 25 | -0.89× | 0.62× | ||
| Q4 24 | -1.05× | 0.29× | ||
| Q3 24 | -3.61× | 0.63× | ||
| Q2 24 | — | -0.62× | ||
| Q1 24 | -1.89× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
NREF
暂无分部数据
